Evotec SE stock plunges after Horizon restructuring announcement signals job cuts and site closures

Evotec SE (ISIN: DE0005664809) unveiled its 'Horizon' transformation plan on March 10, 2026, accelerating cost cuts with up to 800 job reductions and footprint slimming to 10 sites. The move triggered a sharp stock decline on Xetra but aims for €75 million in annual savings by 2027. DACH investors eye the biotech's path to profitability amid pipeline strength.

Evotec SE, the Hamburg-based drug discovery specialist, shocked investors on March 10, 2026, with its 'Horizon' strategic overhaul. The plan includes cutting up to 800 jobs and reducing global sites from 14 to 10, sparking a plunge in its shares on Xetra. This aggressive restructuring responds to normalized demand in drug discovery while targeting €75 million in run-rate savings by end-2027. For DACH investors, the move underscores Evotec's push for agility in a competitive biotech landscape, balancing short-term pain with long-term growth potential in high-value areas like oncology and neurology.

As of: 17.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Evotec's Horizon plan marks a pivotal shift for German life sciences, testing investor patience amid transformation in drug development partnerships.

The Horizon Announcement: What Evotec Changed

Evotec SE detailed 'Horizon' as the next phase of its multi-year transformation, building on 2024's Priority Reset and 2025 priorities. The new operating model rests on three pillars: streamlined operations, focused Centers of Excellence in science, and upgraded commercial execution. This setup aims to boost agility, decision-making speed, and customer responsiveness in drug discovery and preclinical development.

Key actions include optimizing the global footprint to 10 sites over two years, down from 19 in 2024. Workforce adjustments will affect up to 800 positions across locations. Centers of Excellence will centralize expertise in therapeutic areas like oncology, neurology, immunology, and technology platforms including AI-driven innovation.

CEO Dr. Christian Wojczewski emphasized Horizon's role in sustainable growth. The plan positions Evotec for performance through 2027 and scaling toward 2030, amid expectations for scientific and operational excellence.

Financial Impact: Revised Guidance and Savings Target

Preliminary 2025 results showed group revenues near the high end of €760-800 million guidance, at about €788 million. Adjusted EBITDA hit €41 million, beating the €30-50 million range. Just – Evotec Biologics (JEB) drove growth with €259 million revenues, up 40% year-on-year, and €53 million EBITDA contribution.

For 2026, Evotec guided revenues at €700-780 million and adjusted EBITDA at €0-40 million, reflecting Horizon's initial costs. Structural measures promise €75 million run-rate savings by end-2027. A new 2026-2030 framework outlines phased growth, maintaining ambitions despite near-term pressures.

Net debt stood around €111 million in recent estimates, with ongoing biologics momentum providing a buffer. Full 2025 results come April 8, 2026, offering deeper insights into pipeline progress.

Market Reaction: Stock Plunge on Xetra

Evotec SE shares on Xetra plunged following the Horizon news, as restructuring details overshadowed savings potential. Reports noted heavy selling after key chart support failed, reflecting investor concerns over job cuts and site closures. Trading volume spiked amid the volatility.

Analyst responses were mixed. Deutsche Bank held a Neutral rating, while RBC reiterated Buy. The stock's reaction highlights biotech sector sensitivity to cost actions, even when aimed at efficiency.

Evotec trades primarily on Deutsche Börse Xetra in euros, its home market venue. Recent price action on Xetra showed downward pressure post-announcement, underscoring the market's focus on execution risks.

Strategic Rationale: Why Biotech Needs Agility Now

Drug discovery faces normalized demand after pandemic highs, with pharma partners demanding faster, high-value outputs. Evotec's model – fee-for-service, alliances, and proprietary assets – requires leaner operations to compete. Horizon concentrates expertise in Centers of Excellence for oncology, neurology, immunology, and AI integration.

The biologics unit JEB exemplifies strength, with 40% revenue growth signaling scalability in preclinical services. Over 100 proprietary R&D assets, many co-owned, provide upside in therapeutic areas like women's health, nephrology, and antivirals.

This positions Evotec against peers emphasizing integrated platforms. Transformation avoids complacency, targeting operating leverage as AI reshapes discovery timelines.

Risks and Execution Challenges Ahead

Horizon carries execution risks, including talent retention during 800 job cuts and integration hurdles in Centers of Excellence. Revenue guidance for 2026 signals a potential dip, testing balance sheet resilience with €111 million net debt.

Biotech pipelines face clinical uncertainties, regulatory delays, and partner dependencies. Competition from pure-play AI discovery firms adds pressure. If savings lag or growth stalls, investor confidence could erode further.

MSCI ESG rates Evotec AAA, a plus for sustainability-focused funds, but operational shifts must preserve innovation edge. DACH investors should monitor Q1 2026 updates for progress.

Investor Relevance: Opportunities for DACH Portfolios

For German-speaking investors, Evotec represents a pure-play on Europe's biotech resurgence. Hamburg headquarters and Xetra listing align with DACH preferences for liquid, regulated names. Horizon's cost discipline echoes efficiency drives at peers like Sartorius or BioNTech.

Potential BioNTech acquisition rumors, though unconfirmed, highlight partnership value. Strong JEB biologics growth taps outsourcing trends, relevant amid pharma capex caution. Mid-term framework promises leverage if executed well.

With 4,788 employees and global reach, Evotec offers diversified exposure without U.S. volatility. DACH funds tracking MDAX or biotech indices may find value post-dip.

DACH Angle: Home-Market Dynamics and Beyond

As a German SE, Evotec benefits from Cluster Industrial Biotech in Hamburg, fostering local talent and partnerships. Proximity to BioNTech and Bayer aids collaborations, enhancing credibility.

Xetra trading in euros suits DACH retail and institutional flows. Recent Deutsche Bank and RBC coverage reflects strong analyst interest. While global, Evotec's European footprint reduction prioritizes efficiency without losing continental hubs.

For Austrian and Swiss investors, Evotec diversifies beyond U.S. tech-heavy portfolios, with euro exposure hedging currency risks. Horizon tests but reinforces its role in DACH life sciences leadership.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.